Australia approves daily Wegovy tablet as alternative to weekly injections
Juste les faits

Australia approves daily Wegovy tablet as alternative to weekly injections

Résumé

The Therapeutic Goods Administration has registered four strengths of an oral semaglutide tablet for weight management, offering a non-injectable option with similar efficacy to the existing injection.

Australia's Therapeutic Goods Administration (TGA) has approved the first oral formulation of the GLP-1 drug semaglutide, marketed as Wegovy, for weight management. The agency registered tablets in four strengths – 1.5 mg, 4 mg, 9 mg and 25 mg – making it the inaugural GLP-1 medicine available in tablet form in the country.

Semaglutide works by mimicking the hormone glucagon-like peptide-1, which helps regulate blood sugar, appetite and digestion. The daily tablet must be taken on an empty stomach with a small amount of water, followed by a 30-minute wait before eating or drinking anything other than water. In clinical trials, the pill produced an average 14 % reduction in body weight over 64–68 weeks, comparable to the 15 % loss reported for the weekly injection.

"The tablet offers an alternative for people who prefer not to inject or who have difficulty using needles," said a spokesperson for the drug's manufacturer.

Both formats share similar gastrointestinal side effects, such as nausea and diarrhoea, affecting up to 80 % of users. More serious but less common risks include kidney injury, pancreatitis and gallbladder problems. Higher doses can increase the severity of side effects, and doubling the dose does not accelerate weight loss.

The medication is intended for adults with obesity or overweight individuals with related health conditions, and may also be prescribed to reduce cardiovascular risk in patients with heart disease. It is not a quick-fix solution; doctors are advised to incorporate lifestyle counseling and monitor for eating disorders or mental-health concerns.

The TGA approval does not guarantee immediate availability. Novo Nordisk, the manufacturer, plans to launch the tablets by the end of the year pending final packaging and pricing reviews. The drug is not yet listed on the Pharmaceutical Benefits Scheme, so patients will likely pay the full price, which is expected to be similar to the weekly injection that costs between A$250 and A$450 per month.

Experts caution that the tablet should be used alongside a reduced-calorie diet and regular exercise to preserve muscle mass and sustain weight loss, noting that many users regain a substantial portion of lost weight after discontinuing therapy.

Source

1News

Continuez à lire — gratuitement

Créez un compte gratuit pour suivre l'actualité. Aucune carte requise.